iShares Genomics Immunology and Healthcare ETF (IDNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
iShares Genomics Immunology and Healthcare ETF (IDNA) trades at $39.29 with AI Score 47/100 (Grade C). The iShares Genomics Immunology and Healthcare ETF (IDNA) aims to track the investment results of an index focused… Market cap: $184M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for IDNA: IDNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IDNA against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IDNA: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
iShares Genomics Immunology and Healthcare ETF (IDNA) Financial Services Profile
iShares Genomics Immunology and Healthcare ETF (IDNA) offers investors targeted exposure to companies poised to benefit from long-term growth trends in genomics, immunology, and bioengineering. With a focus on both developed and emerging markets, IDNA provides a diversified investment vehicle for capitalizing on innovation within the healthcare sector, while exhibiting a beta of 1.35.
What Is the Investment Thesis for IDNA?
The iShares Genomics Immunology and Healthcare ETF (IDNA) presents an investment opportunity centered on the long-term growth potential of genomics, immunology, and bioengineering. The ETF's focus on companies in both developed and emerging markets allows investors to capitalize on global innovation trends within the healthcare sector. With a beta of 1.35, IDNA exhibits moderate volatility relative to the broader market. Key value drivers include the increasing demand for personalized medicine, the development of novel immunotherapies for cancer and other diseases, and the application of bioengineering technologies to address unmet medical needs. Upcoming catalysts include regulatory approvals for new therapies, advancements in genomic sequencing technologies, and increased investment in healthcare infrastructure in emerging markets. Potential risks include regulatory hurdles, clinical trial failures, and competitive pressures from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
IDNA Key Highlights
Market capitalization of $184M, indicating a relatively small-cap ETF.
- Beta of 1.35, suggesting higher volatility compared to the broader market.
- Exposure to both developed and emerging market companies in the genomics, immunology, and healthcare sectors.
- Focus on companies that could benefit from long-term growth and innovation in these fields.
- Managed by BlackRock, a leading global asset management firm.
Who Are IDNA's Competitors?
IDNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DALI First Trust Dorsey Wright DALI Equity ETF | $29.18 | -0.03% | $110M | 47 |
| DEW WisdomTree Global High Dividend Fund | $72.95 | -0.22% | $143M | 47 |
| ECOW Pacer Emerging Markets Cash Cows 100 ETF | $27.47 | -0.03% | $156M | 50 |
| EMXF iShares ESG Advanced MSCI EM ETF | $56.22 | -0.32% | $163M | 47 |
| EWO iShares MSCI Austria ETF | $43.42 | -0.25% | $182M | 47 |
| MPV Barings Participation Investors | $16.26 | -0.85% | $175M | 67 |
| GGT The Gabelli Multimedia Trust Inc. | $4.11 | -0.24% | $172M | 68 |
| BANX ArrowMark Financial Corp. | $20.70 | +0.95% | $201M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IDNA's Key Strengths?
Exposure to high-growth sectors: genomics, immunology, and bioengineering.
- Diversified portfolio of companies in both developed and emerging markets.
- Managed by BlackRock, a leading global asset management firm.
- Focus on long-term growth trends in innovative healthcare fields.
What Are IDNA's Weaknesses?
Relatively small market capitalization, which may limit liquidity.
- Higher beta compared to the broader market, indicating greater volatility.
- Concentration in specific sectors, which may increase risk.
- Dependence on the performance of companies in the genomics, immunology, and healthcare sectors.
What Could Drive IDNA Stock Higher?
Regulatory approvals for new therapies and medical devices.
- Advancements in genomic sequencing and data analytics.
- Increased investment in healthcare infrastructure in emerging markets.
- Growing demand for personalized medicine and innovative treatments.
What Are the Key Risks for IDNA?
Clinical trial failures and setbacks in drug development.
- Regulatory hurdles and changes in government policies.
- Economic downturns impacting healthcare spending.
- Competitive pressures from established pharmaceutical companies.
- Market volatility and fluctuations in stock prices.
What Are the Growth Opportunities for IDNA?
- Personalized Medicine: The increasing adoption of personalized medicine, driven by advances in genomic sequencing and data analytics, presents a significant growth opportunity for companies in the genomics and healthcare sectors. The global personalized medicine market is projected to reach $2.4 trillion by 2030, growing at a CAGR of 11.2% from 2023. IDNA's exposure to companies involved in genomic sequencing, diagnostics, and targeted therapies positions it to benefit from this trend. Timeline: Ongoing.
- Immunotherapy Advancements: The development of novel immunotherapies for cancer and other diseases is revolutionizing the treatment landscape. The global immunotherapy market is expected to reach $250 billion by 2028, driven by the success of checkpoint inhibitors and CAR-T cell therapies. IDNA's holdings in companies developing and commercializing immunotherapies provide exposure to this high-growth area. Timeline: Ongoing.
- Bioengineering Innovation: Bioengineering technologies, such as gene editing and synthetic biology, are transforming healthcare and creating new opportunities for therapeutic interventions. The global bioengineering market is projected to reach $100 billion by 2027, driven by advancements in CRISPR-Cas9 technology and other gene editing tools. IDNA's exposure to companies involved in gene editing and synthetic biology positions it to capitalize on this emerging field. Timeline: Ongoing.
- Emerging Market Expansion: The increasing healthcare expenditures and growing middle class in emerging markets present a significant growth opportunity for companies in the genomics, immunology, and healthcare sectors. Countries like China and India are investing heavily in healthcare infrastructure and promoting the adoption of innovative therapies. IDNA's exposure to companies with operations in emerging markets allows investors to tap into this growth potential. Timeline: Ongoing.
- Aging Population: The global aging population is driving increased demand for healthcare services and products, particularly in areas such as age-related diseases and chronic conditions. The number of people aged 65 and over is projected to reach 1.6 billion by 2050. IDNA's focus on genomics, immunology, and healthcare aligns with the needs of an aging population, providing exposure to companies developing solutions for age-related health challenges. Timeline: Ongoing.
What Are IDNA's Competitive Advantages?
- Brand recognition and reputation of BlackRock, a leading global asset management firm.
- Diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
- Exposure to both developed and emerging markets.
- Focus on long-term growth trends in innovative healthcare fields.
What Does IDNA Do?
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to provide investors with exposure to companies that are expected to benefit from the ongoing advancements and long-term growth in the fields of genomics, immunology, and bioengineering. Managed by BlackRock, a leading global asset management firm, IDNA seeks to replicate the investment results of an underlying index composed of equities from both developed and emerging markets. The ETF's holdings span a range of companies involved in various aspects of these innovative sectors, including biotechnology firms, pharmaceutical companies, and providers of healthcare services and equipment. IDNA's investment strategy focuses on identifying companies that are at the forefront of genomic research, developing novel immunotherapies, and pioneering bioengineering technologies. By investing in a diversified portfolio of companies within these fields, the ETF aims to capture the potential upside from breakthroughs and advancements that could transform healthcare and improve patient outcomes. The ETF's global reach allows investors to tap into growth opportunities in both established and emerging markets, providing a broader perspective on the evolving landscape of genomics, immunology, and healthcare. As of 2026, IDNA has a market capitalization of $184M.
What Products and Services Does IDNA Offer?
- Tracks the investment results of an index composed of developed and emerging market companies.
- Focuses on companies that could benefit from long-term growth and innovation in genomics.
- Targets companies involved in immunology research and development.
- Includes companies engaged in bioengineering technologies.
- Provides investors with exposure to the healthcare sector.
- Offers a diversified portfolio of companies within these innovative fields.
- Aims to capture the potential upside from breakthroughs and advancements in healthcare.
How Does IDNA Make Money?
- The ETF generates revenue through management fees charged to investors.
- The fund invests in a diversified portfolio of companies in the genomics, immunology, and healthcare sectors.
- The ETF seeks to replicate the investment results of an underlying index.
- The ETF's performance is driven by the growth and innovation of the companies it holds.
What Industry Does IDNA Operate In?
The asset management industry is characterized by increasing competition, evolving regulatory landscapes, and growing demand for specialized investment products. ETFs like IDNA cater to investors seeking targeted exposure to specific sectors or themes, such as genomics and immunology. The global healthcare market is experiencing rapid growth, driven by factors such as an aging population, rising healthcare expenditures, and technological advancements. IDNA's focus on genomics, immunology, and bioengineering aligns with the broader trend towards personalized medicine and innovative therapies. Competitors in the ETF space include firms offering similar thematic or sector-specific investment products.
Who Are IDNA's Key Customers?
- Individual investors seeking exposure to the genomics, immunology, and healthcare sectors.
- Institutional investors looking for thematic investment opportunities.
- Financial advisors seeking to diversify client portfolios.
- Investors interested in long-term growth potential in the healthcare industry.
IDNA Valuation & Market Position
With a $184M market cap, iShares Genomics Immunology and Healthcare ETF sits in the micro-cap segment of the market. Relative to its peer group, IDNA's quantitative score of 47/100 is roughly in line with the peer average of 48/100.
Key Financial Metrics
Return on equity for iShares Genomics Immunology and Healthcare ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. IDNA trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
IDNA Financials
Bull Case vs Bear Case
Bull Case
- IDNA's focus on genomics and immunology aligns with long-term healthcare innovation trends, suggesting sustained investor interest.
- Recent positive developments in gene editing technologies could boost the perceived value of companies within the IDNA ETF.
- Strong community buzz around personalized medicine advancements creates a positive sentiment tailwind for IDNA.
- Increased public awareness of immune system health, post-pandemic, may drive further investment into related healthcare sectors covered by IDNA.
Bear Case
- Uncertainty surrounding regulatory approvals for novel therapies within the genomics and immunology space could dampen investor enthusiasm for IDNA.
- Negative social sentiment regarding the high cost of gene therapies might create headwinds for companies held within the ETF.
- Broader market corrections impacting the healthcare sector could disproportionately affect specialized ETFs like IDNA.
- Concerns about ethical implications of certain genomic technologies, voiced within the community, may lead to decreased investment in IDNA.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IDNA Latest News
IDNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IDNA.
Price Targets
Wall Street price target analysis for IDNA.
IDNA MoonshotScore
What does this score mean?
The MoonshotScore rates IDNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Common Questions About IDNA (Financial Services)
What does the AI Score mean for IDNA?
IDNA holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. The iShares Genomics Immunology and Healthcare ETF (IDNA) aims to track the investment results of an index focused on companies benefiting from advancements in genomics, immunology, …
What does iShares Genomics Immunology and Healthcare ETF do?
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. The ETF provides investors with targeted exposure to companies involved in genomic sequencing, immunotherapy development, and bioengineering technologies.
What are the main risks for IDNA?
The main risks for IDNA include regulatory hurdles, clinical trial failures, and competitive pressures from established pharmaceutical companies. The genomics, immunology, and bioengineering sectors are subject to strict regulatory oversight, and delays or unfavorable decisions could impact the performance of companies in the ETF's portfolio. Clinical trial failures can also negatively affect the value of biotechnology and pharmaceutical companies.
How is iShares Genomics Immunology and Healthcare ETF adapting to fintech disruption?
As an ETF, iShares Genomics Immunology and Healthcare ETF (IDNA) indirectly adapts to fintech disruption through the companies it holds within its portfolio. The ETF's success depends on the ability of its constituent companies to leverage fintech innovations to improve healthcare delivery, develop new therapies, and enhance patient outcomes.
What regulatory challenges does iShares Genomics Immunology and Healthcare ETF face?
As an ETF, iShares Genomics Immunology and Healthcare ETF (IDNA) is subject to regulations governing investment companies and ETFs. These regulations include requirements for diversification, liquidity, and transparency. The ETF must also comply with securities laws and regulations related to trading and disclosure.
What are the key factors to evaluate for IDNA?
iShares Genomics Immunology and Healthcare ETF (IDNA) holds an AI score of 47/100 (low). The iShares Genomics Immunology and Healthcare ETF (IDNA) presents an investment opportunity centered on the long-term growth potential of genomics, immunology, and bioengineering. Not financial advice.
How frequently does IDNA data refresh on this page?
IDNA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IDNA's recent stock price performance?
iShares Genomics Immunology and Healthcare ETF (IDNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Exposure to high-growth sectors: genomics, immunology, and bioengineering. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IDNA overvalued or undervalued right now?
iShares Genomics Immunology and Healthcare ETF (IDNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The analysis is based on publicly available information and may be subject to change.
- AI analysis is pending for IDNA, which may provide additional insights.
- Investment decisions should be based on individual risk tolerance and financial circumstances.